Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers

The sodium glucose co‐transporter‐2 inhibitor dapagliflozin has been shown to decrease urinary albumin‐to‐creatinine ratio (UACR). This effect, however, varies among individual patients. In this study, we assessed the baseline characteristics and concurrent changes in other cardiovascular risk marke...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Obes Metab
Autors principals: Heerspink, Hiddo J. L., Sjöström, C. David, Inzucchi, Silvio E., Hallow, Melissa K., Cain, Valerie A., Rossing, Peter, Stefansson, Bergur V., Sartipy, Peter
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2018
Matèries:
Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590413/
https://ncbi.nlm.nih.gov/pubmed/30414240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13579
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars